Clinical Trials in the UK / NCT06824129
Active, not recruiting
Observational
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
NCT06824129 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Complicated Urinary Tract Infection
Study summary
Performance evaluation of QIAstat-Dx cUTI Plus AMR Panel using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment
Eligibility
Inclusion Criteria:
* Specimens from subjects of all ages and demographic characteristics can be enrolled.
* Specimen must come from patients with suspected cUTI by their healthcare provider:
* Urine specimen with evidence of pyuria confirmed by positive urine analysis (Dipstick analysis positive for leukocyte esterase or at least 10 White Blood Cells percubic millimeter) And
* A sign or symptom of a cUTI (for example: chills or rigors or warmth associated with fever, malaise, flank pain or pelvic pain and/or costo-vertebral angle pain or tenderness on physical examination, nausea or vomiting, dysuria, urinary frequency or urinary urgency)
* Specimen must be residual leftover and de-identified
* Specimen obtained preserved (containing boric acid, sodium formate or sodium borate) or unpreserved as midstream urine or fresh urine catheter
* For Preserved Only: Fresh prospectively collected preserved specimens stored to up 48 hours at 15°C-25°C or 24 hours at 2°C-8°C.
* For Unpreserved Only: Fresh prospectively collected unpreserved specimens stored up to 24 hours at 2°C-8°C.
* Specimen must have a minimum of 3 ml of urine available.
* Specimen date of collection and standard of Care testing results should be available.
* Specimen must be unique (only one sample enrolled per patient).
Exclusion Criteria:
* Specimens enrolled in the study may be excluded for the following reasons:
* Lack of clear subject identification or label on urine specimen.
* Specimen has been centrifuged.
* Obvious physical damage of residual specimen.
Primary outcome measure(s)
- PPA — 8 months
Positive percent agreement - NPA — 8 months
Negative percent agreement
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| QIAGEN | Manchester | United Kingdom |
More QIAGEN Gaithersburg, Inc trials in the UK
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06824129 on ClinicalTrials.gov ↗ ← All trials in the UK